Ana Uribarri Cisneros
About Ana Uribarri Cisneros
Ana Uribarri Cisneros is the Brand Lead IO Pan-tumor for Spain and Portugal at Bristol Myers Squibb, with extensive experience in oncology commercial strategy and a strong background in business administration and life sciences.
Company
Ana Uribarri Cisneros is currently employed at Bristol Myers Squibb. She holds the position of Brand Lead IO Pan-tumor for Spain and Portugal, focusing on immuno-oncology brand strategy across these regions.
Title
Ana Uribarri Cisneros serves as the Brand Lead IO Pan-tumor for Spain and Portugal at Bristol Myers Squibb. Her role encompasses managing the brand strategies for oncology treatments within these geographical areas.
Professional Background
Ana Uribarri Cisneros has a notable background in oncology commercial strategy. Before joining Bristol Myers Squibb, she amassed several years of experience at Pfizer. From 2017 to 2020, she served as Oncology Commercial Strategy Manager. Prior to that, she held various positions including Oncology Jr. Commercial Strategy Manager, Associate Brand Manager Internal Medicine, and Marketing Trainee Internal Medicine.
Education and Expertise
Ana Uribarri Cisneros has a strong academic foundation combining business administration and life sciences. She earned a Degree in Biology specializing in Biochemistry and Molecular Biology from Universidad Autónoma de Madrid and later a Degree in Business Administration and Management from Universidad Nacional de Educación a Distancia. Additionally, she holds a Master's degree in Biotechnology from ALITER, Escuela Internacional de Negocios, and has international academic experience from an Erasmus Exchange program at Högskolan i Halmstad in Sweden.
Achievements
Ana Uribarri Cisneros has been leading the brand strategy for immuno-oncology across Spain and Portugal since July 2020. Her extensive experience in oncology commercial strategy is complemented by her roles at Pfizer and her diverse academic background. These achievements highlight her expertise in both the biopharmaceutical industry and oncology brand management.